Y. Iwama

Divergence of dose–response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study

T. Kinoshita, H. Ogata, Y. Koshikawa, 2021, CNS Spectrums.

Efficacy Comparison for a Schizophrenia and a Dysuria Drug Among East Asian Populations: A Retrospective Analysis Using Multi-regional Clinical Trial Data

Yoshiro Saito, M. Tohkin, Y. Uyama, 2021, Therapeutic Innovation & Regulatory Science.

[Evaluation of the safety and efficacy of cefditoren pivoxil fine granules for pediatric use in pediatric patients with acute otitis media].

Yuji Sasagawa, Yoshikazu Sato, Hitoshi Yamada, 2010, The Japanese Journal of Antibiotics.

Asenapine add‐on treatment for schizophrenia adults who received antipsychotics: A 52‐week, open‐label study

N. Iwata, T. Kishi, Yuji Sasagawa, 2023, Psychiatry and clinical neurosciences.

Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication

T. Kinoshita, Y. Takekita, Y. Iwama, 2023, Neuropsychopharmacology reports.

Predictors of continuation for asenapine from real-world data in patients with schizophrenia

Y. Koshikawa, Y. Takekita, Nobuatsu Aoki, 2024, Annals of general psychiatry.

Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real‐world data

Y. Koshikawa, Y. Takekita, Nobuatsu Aoki, 2023, Neuropsychopharmacology reports.